Skip to content

The trial of Xinluosu Tablets effects on human platelet aggregation function

The trial of Xinluosu Tablets effects on human platelet aggregation function

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048885
Enrollment
Unknown
Registered
2021-07-19
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy folks

Interventions

Experimental group:Xinluosu Tablets 300mg po qd
Control group:placebo 300mg po qd

Sponsors

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 35 to 65 years, and in good health; 2. No diseases of brain, heart, liver, lung, kidney, blood vessel, digestion or blood,no history of long-term medication; 3. No abnormal in laboratory tests(blood/urine routine test, hepatic and renal function tests and etc); 4. Provides written permission and volunteered to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Obvious vascular or hematologic disease, hypertension or infection; 2. Suffering from systemic diseases of lung, brain, liver, kidney, digestion and hematopoiesis, mental illness or severe neurosis; 3. Take anti-platelet drugs, traditional Chinese medicine for promoting blood circulation and removing blood stasis, or other drugs that can change the function of platelets or the coagulation system; 4. Abnormal platelet count(whole blood300x10^9/mL); 5. Low HCT(M<40%,F<37%); 6. PT is outside the normal reference range; 7. Low hemoglobin count(M<120g/L,F<110g/L); 8. Normal menstrual cycle, taking OC or hormone replacement therapy; 9. Pregnant and lactating women; 10. Have taken fish oil and evening primrose oil supplements within a month; 11. Not suitable for intravenous blood collection personnel; 12. Subjects should not donate more than 560ml of blood within a month; 13. Allergy to tomatoes and their ingredients; 14. Patients with gastric ulcer.

Design outcomes

Primary

MeasureTime frame
platelet aggregation function ;platelet activating function;platelet release function;plablet adhesion function;

Secondary

MeasureTime frame
stature;weight;waist circumference;hip circumference;blood pressure;heart rate;Score of TCM constitution;blood routine test;hepatic function test;renal function test;blood lipid test;hemagglutination test;

Countries

China

Contacts

Public ContactZhao Mingjing

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

mjgx2004@163.com+86 13161928227

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026